W. Gullick

发表

Pathobiological characteristics of the 1st primary and risk of metachronous contralateral invasive breast-carcinoma - clinical implications.

N. Weidner, N. Lemoine, P. Boracchi, 1993, International journal of oncology.

Production and characterization of monoclonal antibodies to the c-erbB-2 proto-oncogene protein using a synthetic peptide immunogen.

W. Gullick, D. Venter, C. Dean, 1988, Biochemical Society transactions.

Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.

M. Sternberg, W. Gullick, H. Hurst, 1993, Oncogene.

Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancer

T. Powles, B. Gusterson, W. Gullick, 1988, International journal of cancer.

Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.

N. Hynes, W. Gullick, R. Beerli, 1996, Oncogene.

c-erbB2 amplification and overexpression in human tumors.

W. Gullick, F. Lofts, 1992, Cancer treatment and research.

Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ

D. Barnes, J. Meyer, W. Gullick, 1991, Breast Cancer Research and Treatment.

Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors.

N. Normanno, D. Salomon, F. Ciardiello, 1992, Cancer research.

Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.

P Boracchi, F Pozza, P. Boracchi, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of the c‐erbB‐3 gene product in gastric cancer

N. Lemoine, D. Levison, N. Lemoine, 1993, International journal of cancer.

Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families.

N. Normanno, A. De Luca, D. Salomon, 1999, International journal of oncology.

The immunohistochemical detection of cripto‐1 in benign and malignant human bladder

D. Neal, M. Robinson, W. Gullick, 1998, The Journal of pathology.

Expression of amphiregulin, cripto-1, and heregulin-alpha in human breast-cancer cells.

Y. Yarden, N. Normanno, D. Salomon, 1993, International journal of oncology.

c-erbB-3 proto-oncogene expression in uterine cervical carcinoma

C. H. Buckley, W. Gullick, T. Rajkumar, 1994, International Journal of Gynecologic Cancer.

Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes

W. Gullick, G. Picco, S. Chin, 2006, Breast Cancer Research.

ASSOCIATION OF C-ERBB-2 ONCOPROTEIN EXPRESSION WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST-CANCER

J. Cairns, B. Angus, W. Gullick, 1989 .

Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4

B. Angus, W. Gullick, R. Leonard, 2003, Journal of clinical pathology.

Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation

W. Gullick, N. Dibb, M. Uden, 1999, Oncogene.

c-erbB-2, a Tyrosine Kinase Growth Factor Receptor and its Role in Breast Cancer

W. Gullick, F. Lofts, 1992 .

c‐erbB‐2 oncogene expression in ovarian cancer

W. Gullick, W. Gullick, C. Hughes, 1990, The Journal of pathology.

Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas.

G. Merlo, Chen-feng Qi, N. Normanno, 1994, British Journal of Cancer.

Immunohistochemical detection of cripto-1, amphiregulin and transforming growth-factor-alpha in human gastric carcinomas and intestinal metaplasias.

N. Normanno, S. Takashima, W. Gullick, 1994, International journal of oncology.

An immunohistochemical study of the presence of c‐erbB‐2 protein in Paget's disease of the nipple

D. Barnes, W. Gullick, R. Millis, 1989, Histopathology.

Avoiding Punishment Is Its Own Reward

N. Lemoine, N. Lemoine, W. Gullick, 1991, British Journal of Cancer.

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

I. Ellis, R. Blamey, R. Nicholson, 1998, Oncogene.

Prognostic value of epidermal growth factor receptor expression in cervical carcinoma.

H. Fox, C. H. Buckley, W. Gullick, 1993, Journal of clinical pathology.

Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

J. Bártková, D. Barnes, W. Gullick, 1990, Human pathology.

c-erbB-2 oncoprotein expression in malignant and nonmalignant breast tissue

W. Gullick, D. Carney, A. McCann, 1989, Irish journal of medical science.

Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.

W. Gullick, W. Gullick, 1991, British medical bulletin.

Amphiregulin and cripto overexpression in breast-cancer - relationship with prognosis and clinical and molecular-variables.

L. Bobrow, D. Barnes, W. Gullick, 1995, International journal of oncology.

Expression of cripto-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia.

S. Takashima, W. Gullick, K. Mandai, 1994, International journal of oncology.

Immunolocalization of criptoregulin and amphiregulin in rectal-cancer - correlation with prognosis.

I. Talbot, J. Northover, E. Lalani, 1994, International Journal of Oncology.

Cripto-1 is a tumour specific marker of bladder cancer

D. Neal, M. Robinson, W. Gullick, 1997 .

Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.

P. Boracchi, G. Gasparini, W. Gullick, 1992 .